Natural Sunlight Driven Photocatalytic Removal of Toxic Textile Dyes in Water Using B-Doped ZnO/TiO₂ Nanocomposites

A novel B-doped ZnO/TiO2 (B–ZnO/TiO2) nanocomposite photocatalyst was prepared using a mechanochemical–calcination method. For the characterization of the synthesized B–ZnO/TiO2 photocatalyst, XRD, FESEM-EDS, FTIR, UV-Vis DRS, BET, PL, and XPS techniques were used. The bandgap energy of B–ZnO/TiO2 was reduced, resulting in enhanced visible-light absorption. Significant PL quenching confirmed the reduction in the electron–hole recombination rate. Furthermore, reduced crystallite size and a larger surface area were obtained. Hence, the B–ZnO/TiO2 photocatalyst exhibited better photocatalytic activity than commercial TiO2, ZnO, B–ZnO, and ZnO/TiO2 in the removal of methylene blue (MB) dye under natural sunlight irradiation. The effects of various parameters, such as initial concentration, photocatalyst amount, solution pH, and irradiation time, were studied. Under optimal conditions (MB concentration of 15 mg/L, pH 11, B–ZnO/TiO2 amount of 30 mg, and 15 min of operation), a maximum MB removal efficiency of ~95% was obtained. A plausible photocatalytic degradation mechanism of MB with B–ZnO/TiO2 was estimated from the scavenger test, and it was observed that the •O2− and •OH radicals were potential active species for the MB degradation. Cyclic experiments indicated the high stability and reusability of B–ZnO/TiO2, which confirmed that it can be an economical and environmentally friendly photocatalyst

Natural Sunlight Driven Photocatalytic Removal of Toxic Textile Dyes in Water Using B-Doped ZnO/TiO2 Nanocomposites

A novel B-doped ZnO/TiO2 (B–ZnO/TiO2) nanocomposite photocatalyst was prepared using a mechanochemical–calcination method. For the characterization of the synthesized B–ZnO/TiO2 photocatalyst, XRD, FESEM-EDS, FTIR, UV-Vis DRS, BET, PL, and XPS techniques were used. The bandgap energy of B–ZnO/TiO2 was reduced, resulting in enhanced visible-light absorption. Significant PL quenching confirmed the reduction in the electron–hole recombination rate. Furthermore, reduced crystallite size and a larger surface area were obtained. Hence, the B–ZnO/TiO2 photocatalyst exhibited better photocatalytic activity than commercial TiO2, ZnO, B–ZnO, and ZnO/TiO2 in the removal of methylene blue (MB) dye under natural sunlight irradiation. The effects of various parameters, such as initial concentration, photocatalyst amount, solution pH, and irradiation time, were studied. Under optimal conditions (MB concentration of 15 mg/L, pH 11, B–ZnO/TiO2 amount of 30 mg, and 15 min of operation), a maximum MB removal efficiency of ~95% was obtained. A plausible photocatalytic degradation mechanism of MB with B–ZnO/TiO2 was estimated from the scavenger test, and it was observed that the •O2− and •OH radicals were potential active species for the MB degradation. Cyclic experiments indicated the high stability and reusability of B–ZnO/TiO2, which confirmed that it can be an economical and environmentally friendly photocatalyst

Trachoma: protective and pathogenic ocular immune responses to Chlamydia trachomatis.

Trachoma, caused by Chlamydia trachomatis (Ct), is the leading infectious blinding disease worldwide. Chronic conjunctival inflammation develops in childhood and leads to eyelid scarring and blindness in adulthood. The immune response to Ct provides only partial protection against re-infection, which can be frequent. Moreover, the immune response is central to the development of scarring pathology, leading to loss of vision. Here we review the current literature on both protective and pathological immune responses in trachoma. The resolution of Ct infection in animal models is IFNγ-dependent, involving Th1 cells, but whether this is the case in human ocular infection still needs to be confirmed. An increasing number of studies indicate that innate immune responses arising from the epithelium and other innate immune cells, along with changes in matrix metalloproteinase activity, are important in the development of tissue damage and scarring. Current trachoma control measures, which are centred on repeated mass antibiotic treatment of populations, are logistically challenging and have the potential to drive antimicrobial resistance. A trachoma vaccine would offer significant advantages. However, limited understanding of the mechanisms of both protective immunity and immunopathology to Ct remain barriers to vaccine development